董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Katina Dorton | 女 | Independent Director | 68 | 13.91万美元 | 14.04 | 2026-05-20 |
| Stephen Biggar | 男 | Chair of the Board and Independent Director | 55 | 16.22万美元 | 9.16 | 2026-05-20 |
| Gavin MacBeath | 男 | Chief Executive Officer and Director | 56 | 280.15万美元 | 166.38 | 2026-05-20 |
| Barbara Klencke | 女 | Independent Director | 68 | 14.58万美元 | 16.32 | 2026-05-20 |
| Gabriela Gruia | 女 | Independent Director | 69 | 12.91万美元 | 10.99 | 2026-05-20 |
| Garry Nicholson | 男 | Independent Director | 71 | 12.54万美元 | 6.26 | 2026-05-20 |
| R. Keith Woods | 男 | Independent Director | 58 | 12.53万美元 | 6.50 | 2026-05-20 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Zoran Zdraveski | 男 | Chief Legal and Strategy Officer and Secretary | 56 | 未披露 | 未持股 | 2026-05-20 |
| Gavin MacBeath | 男 | Chief Executive Officer and Director | 56 | 280.15万美元 | 166.38 | 2026-05-20 |
| Jason A. Amello | 男 | Chief Financial Officer and Treasurer | 57 | 127.60万美元 | 52.75 | 2026-05-20 |
| Chrystal Louis | 女 | Chief Medical Officer | 50 | 160.96万美元 | 33.12 | 2026-05-20 |
董事简历
中英对照 | 中文 | 英文- Katina Dorton
-
Katina Dorton，自2021年3月起担任董事会成员。Dorton女士还担任Fulcrum Therapeutics, Inc.的董事会成员、审计委员会主席、薪酬和人力资本管理委员会成员，自2020年1月起，担任董事会成员、审计委员会主席，并自2024年2月起担任万灵科 PLC的人力资源和薪酬委员会成员。此外，Dorton女士在2014年至2022年期间一直是美国生态，Inc.的董事会成员，直至其被共和废品处理公司收购。Dorton女士还在2020年至2021年被默克制药公司收购之前担任生物制药公司Pandion Therapeutics, Inc.的董事会成员和审计委员会主席。此前，Dorton女士曾在多家生物技术公司担任首席财务官职务，包括Nodthera Inc.，一家在2020年至2022年开发抑制NLRP3炎性体药物的公司，Repare Therapeutics Inc.，一家在2019年至2020年期间专注于合成杀伤力和DNA修复的肿瘤学公司，AVROBIO，Inc.，2017年至2018年期间是一家慢病毒基因治疗公司，以及2015年至2017年期间的生物技术公司Immatics GmbH。在其职业生涯的早期，Dorton女士曾在摩根士丹利和Needham & Company担任投资银行业务的董事总经理，并在Sullivan & Cromwell担任律师。Dorton女士获得了弗吉尼亚大学法学院的法学博士学位、乔治华盛顿大学的工商管理硕士学位和杜克大学的学士学位。Dorton女士获得了NACD董事认证。
Katina Dorton has served as a member of TScan Therapeutics, Inc. board of directors since March 2021. Ms. Dorton also serves as a member of the board of directors, as chair of the audit committee, and as a member of the compensation and human capital management committee of Fulcrum Therapeutics, Inc., since January 2020, as a member of the board of directors, as Chair of the Compensation Committee, and as a member of the audit committee of Mallinckrodt plc since February 2024. Ms. Dorton also serves as a member of the board of directors of Prelude Therapeutics and Chair of the Audit Committee. In addition, Ms. Dorton was a member of the board of directors of US Ecology, Inc., from 2014 to 2022 until its acquisition by Republic Services, Inc.Ms. Dorton also served as a member of the board of directors and chair of the audit committee of Pandion Therapeutics, Inc., a biopharmaceutical company, from 2020 until its acquisition by Merck & Co., Inc., in 2021. Previously, Ms. Dorton held CFO positions at several biotechnology companies, including Nodthera Inc., a company developing medicines to inhibit the NLRP3 inflammasome from 2020 to 2022, Repare Therapeutics Inc., a synthetic lethality and DNA repair focused oncology company from 2019 to 2020, AVROBIO, Inc., a lentiviral gene therapy company from 2017 through 2018, and Immatics GmbH, a biotechnology company from 2015 through 2017. Earlier in her career, Ms. Dorton served as a Managing Director in investment banking for Morgan Stanley and Needham & Company and as an attorney at Sullivan & Cromwell. Ms. Dorton received her J.D. from the University of Virginia School of Law, her M.B.A. from George Washington University and her B.A. from Duke University. Ms. Dorton is NACD Directorship Certified. - Katina Dorton，自2021年3月起担任董事会成员。Dorton女士还担任Fulcrum Therapeutics, Inc.的董事会成员、审计委员会主席、薪酬和人力资本管理委员会成员，自2020年1月起，担任董事会成员、审计委员会主席，并自2024年2月起担任万灵科 PLC的人力资源和薪酬委员会成员。此外，Dorton女士在2014年至2022年期间一直是美国生态，Inc.的董事会成员，直至其被共和废品处理公司收购。Dorton女士还在2020年至2021年被默克制药公司收购之前担任生物制药公司Pandion Therapeutics, Inc.的董事会成员和审计委员会主席。此前，Dorton女士曾在多家生物技术公司担任首席财务官职务，包括Nodthera Inc.，一家在2020年至2022年开发抑制NLRP3炎性体药物的公司，Repare Therapeutics Inc.，一家在2019年至2020年期间专注于合成杀伤力和DNA修复的肿瘤学公司，AVROBIO，Inc.，2017年至2018年期间是一家慢病毒基因治疗公司，以及2015年至2017年期间的生物技术公司Immatics GmbH。在其职业生涯的早期，Dorton女士曾在摩根士丹利和Needham & Company担任投资银行业务的董事总经理，并在Sullivan & Cromwell担任律师。Dorton女士获得了弗吉尼亚大学法学院的法学博士学位、乔治华盛顿大学的工商管理硕士学位和杜克大学的学士学位。Dorton女士获得了NACD董事认证。
- Katina Dorton has served as a member of TScan Therapeutics, Inc. board of directors since March 2021. Ms. Dorton also serves as a member of the board of directors, as chair of the audit committee, and as a member of the compensation and human capital management committee of Fulcrum Therapeutics, Inc., since January 2020, as a member of the board of directors, as Chair of the Compensation Committee, and as a member of the audit committee of Mallinckrodt plc since February 2024. Ms. Dorton also serves as a member of the board of directors of Prelude Therapeutics and Chair of the Audit Committee. In addition, Ms. Dorton was a member of the board of directors of US Ecology, Inc., from 2014 to 2022 until its acquisition by Republic Services, Inc.Ms. Dorton also served as a member of the board of directors and chair of the audit committee of Pandion Therapeutics, Inc., a biopharmaceutical company, from 2020 until its acquisition by Merck & Co., Inc., in 2021. Previously, Ms. Dorton held CFO positions at several biotechnology companies, including Nodthera Inc., a company developing medicines to inhibit the NLRP3 inflammasome from 2020 to 2022, Repare Therapeutics Inc., a synthetic lethality and DNA repair focused oncology company from 2019 to 2020, AVROBIO, Inc., a lentiviral gene therapy company from 2017 through 2018, and Immatics GmbH, a biotechnology company from 2015 through 2017. Earlier in her career, Ms. Dorton served as a Managing Director in investment banking for Morgan Stanley and Needham & Company and as an attorney at Sullivan & Cromwell. Ms. Dorton received her J.D. from the University of Virginia School of Law, her M.B.A. from George Washington University and her B.A. from Duke University. Ms. Dorton is NACD Directorship Certified.
- Stephen Biggar
-
Stephen Biggar自2021年3月起担任TScan Therapeutics公司董事会成员，并自2024年6月起担任TScan Therapeutics公司董事会主席。Biggar博士是Baker Bros. Advisors LP（“Baker Bros.”）的合伙人，该公司是一家专注于生物技术的投资顾问。Biggar博士于2000年4月加入贝克兄弟公司。Biggar博士在Kiniksa制药 International，plc.和Acadia Pharmaceuticals Inc.的董事会任职。Biggar博士获得斯坦福大学免疫学医学博士和博士学位，并获得罗切斯特大学遗传学学士学位。
Stephen Biggar has served as a member of TScan Therapeutics, Inc. board of directors since March 2021 and has served as chair of TScan Therapeutics, Inc. board of directors since June 2024. Dr. Biggar is a partner at Baker Bros. Advisors LP ("Baker Bros."), a biotechnology focused investment advisor. Dr. Biggar joined Baker Bros. in April 2000. Dr. Biggar serves on the boards of Kiniksa Pharmaceuticals International, plc. and Acadia Pharmaceuticals Inc. Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester. - Stephen Biggar自2021年3月起担任TScan Therapeutics公司董事会成员，并自2024年6月起担任TScan Therapeutics公司董事会主席。Biggar博士是Baker Bros. Advisors LP（“Baker Bros.”）的合伙人，该公司是一家专注于生物技术的投资顾问。Biggar博士于2000年4月加入贝克兄弟公司。Biggar博士在Kiniksa制药 International，plc.和Acadia Pharmaceuticals Inc.的董事会任职。Biggar博士获得斯坦福大学免疫学医学博士和博士学位，并获得罗切斯特大学遗传学学士学位。
- Stephen Biggar has served as a member of TScan Therapeutics, Inc. board of directors since March 2021 and has served as chair of TScan Therapeutics, Inc. board of directors since June 2024. Dr. Biggar is a partner at Baker Bros. Advisors LP ("Baker Bros."), a biotechnology focused investment advisor. Dr. Biggar joined Baker Bros. in April 2000. Dr. Biggar serves on the boards of Kiniksa Pharmaceuticals International, plc. and Acadia Pharmaceuticals Inc. Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and received a B.S. in Genetics from the University of Rochester.
- Gavin MacBeath
-
Gavin MacBeath自2023年5月起担任TScan Therapeutics，Inc.首席执行官和TScan Therapeutics，Inc.董事会成员。他此前于2023年3月至2023年5月担任TScan Therapeutics，Inc.代理首席执行官，于2018年12月至2023年5月担任TScan Therapeutics，Inc.首席科学和运营官。他在学术界和工业界拥有超过二十年的经验，创立公司并推动研究从早期发现到药物批准。在加入TScan之前，MacBeath博士于2017年3月至2018年7月在Abpro Corporation担任首席科学官，通过临床前开发推进T细胞接合双特异性抗体。此前，MacBeath博士是Merrimack制药的联合创始人，曾于2010年2月至2014年2月担任转化研究主管，并于2014年2月至2016年10月担任Discovery高级副总裁。麦克比思博士的学术生涯始于此，他曾担任哈佛大学鲍尔基因组学研究中心的首位研究员，担任哈佛大学化学与化学生物学系的助理教授和后来的副教授，并担任哈佛医学院的讲师和首席研究员。MacBeath博士在马尼托巴大学获得本科学位，在斯克里普斯研究所获得博士学位，并在哈佛大学与Stuart Schreiber博士一起接受博士后培训。
Gavin MacBeath has served as TScan Therapeutics, Inc. Chief Executive Officer and as a member of TScan Therapeutics, Inc. board of directors since May 2023. He was previously TScan Therapeutics, Inc. acting Chief Executive Officer from March 2023 to May 2023, and TScan Therapeutics, Inc. Chief Scientific and Operating Officer from December 2018 to May 2023. He has over two decades of experience in academia and industry, founding companies and driving research from early stage discovery through drug approval. Prior to joining TScan, Dr. MacBeath served as the Chief Scientific Officer at Abpro Corporation from March 2017 to July 2018, where he advanced T cell engaging bispecific antibodies through pre clinical development. Previously, Dr. MacBeath was a co founder of Merrimack Pharmaceuticals, where he served as Head of Translational Research from February 2010 to February 2014 and as Senior Vice President of Discovery from February 2014 to October 2016. Dr. MacBeath began his career in academia, where he served as the first fellow at Harvard's Bauer Center for Genomics Research, as an Assistant Professor and later Associate Professor in the Department of Chemistry & Chemical Biology at Harvard University, and as Lecturer and Principal Investigator at Harvard Medical School. Dr. MacBeath received his undergraduate degree from the University of Manitoba, his Ph.D. from The Scripps Research Institute, and postdoctoral training with Dr. Stuart Schreiber at Harvard University. - Gavin MacBeath自2023年5月起担任TScan Therapeutics，Inc.首席执行官和TScan Therapeutics，Inc.董事会成员。他此前于2023年3月至2023年5月担任TScan Therapeutics，Inc.代理首席执行官，于2018年12月至2023年5月担任TScan Therapeutics，Inc.首席科学和运营官。他在学术界和工业界拥有超过二十年的经验，创立公司并推动研究从早期发现到药物批准。在加入TScan之前，MacBeath博士于2017年3月至2018年7月在Abpro Corporation担任首席科学官，通过临床前开发推进T细胞接合双特异性抗体。此前，MacBeath博士是Merrimack制药的联合创始人，曾于2010年2月至2014年2月担任转化研究主管，并于2014年2月至2016年10月担任Discovery高级副总裁。麦克比思博士的学术生涯始于此，他曾担任哈佛大学鲍尔基因组学研究中心的首位研究员，担任哈佛大学化学与化学生物学系的助理教授和后来的副教授，并担任哈佛医学院的讲师和首席研究员。MacBeath博士在马尼托巴大学获得本科学位，在斯克里普斯研究所获得博士学位，并在哈佛大学与Stuart Schreiber博士一起接受博士后培训。
- Gavin MacBeath has served as TScan Therapeutics, Inc. Chief Executive Officer and as a member of TScan Therapeutics, Inc. board of directors since May 2023. He was previously TScan Therapeutics, Inc. acting Chief Executive Officer from March 2023 to May 2023, and TScan Therapeutics, Inc. Chief Scientific and Operating Officer from December 2018 to May 2023. He has over two decades of experience in academia and industry, founding companies and driving research from early stage discovery through drug approval. Prior to joining TScan, Dr. MacBeath served as the Chief Scientific Officer at Abpro Corporation from March 2017 to July 2018, where he advanced T cell engaging bispecific antibodies through pre clinical development. Previously, Dr. MacBeath was a co founder of Merrimack Pharmaceuticals, where he served as Head of Translational Research from February 2010 to February 2014 and as Senior Vice President of Discovery from February 2014 to October 2016. Dr. MacBeath began his career in academia, where he served as the first fellow at Harvard's Bauer Center for Genomics Research, as an Assistant Professor and later Associate Professor in the Department of Chemistry & Chemical Biology at Harvard University, and as Lecturer and Principal Investigator at Harvard Medical School. Dr. MacBeath received his undergraduate degree from the University of Manitoba, his Ph.D. from The Scripps Research Institute, and postdoctoral training with Dr. Stuart Schreiber at Harvard University.
- Barbara Klencke
-
Barbara Klencke，自2021年11月起担任董事会成员。Klencke博士自2015年起担任Sierra Oncology公司的首席医疗官和首席开发官，该公司是一家上市的临床阶段生物制药公司。同时，她从2017年开始担任Lexent Bio的独立董事，直到2020年该公司被Foundation Medicine收购。2011年至2015年，Klencke博士在Onyx制药公司担任全球开发高级副总裁，该公司于2013年被安进公司收购。2003年至2011年在基因泰克公司工作期间，她还领导了各种早期和晚期肿瘤学项目。她在加州大学旧金山分校完成了内科和血液学/肿瘤学培训，并在1995年至2002年期间继续担任肿瘤学助理教授，专注于临床研究。Klencke博士拥有印第安纳大学的学士学位和加州大学戴维斯分校的医学博士学位。
Barbara Klencke has served as a member of TScan Therapeutics, Inc. board of directors since April 2023. She also currently serves as an independent board member of Xencor since September 2023 and Immune Onc Therapeutics, Inc. since 2022. She has previously served as an independent board member of ALX Oncology in 2025, eFFECTOR Therapeutics, Inc. from 2021 until 2024 and Lexent Bio from 2017 until that company's acquisition by Foundation Medicine in 2020. Dr. Klencke is currently serving as Chief Medical Officer of ALX Oncology, and previously served as the Chief Medical and Chief Development Officer of Sierra Oncology Inc. from 2015 until 2023 following its acquisition by GlaxoSmithKline plc in 2022. From 2011 to 2015, Dr. Klencke served as SVP, Global Development, at Onyx Pharmaceuticals, which was acquired by Amgen Inc., in 2013. She also led a variety of both early and late stage oncology programs while at Genentech, Inc. from 2003 to 2011. She completed Internal Medicine and Hematology/Oncology training at the University of California, San Francisco and remained there as an Assistant Professor of Medicine in Oncology focusing on clinical research from 1995 to 2002. Dr. Klencke holds a B.S. from Indiana University and an M.D. from the University of California, Davis. - Barbara Klencke，自2021年11月起担任董事会成员。Klencke博士自2015年起担任Sierra Oncology公司的首席医疗官和首席开发官，该公司是一家上市的临床阶段生物制药公司。同时，她从2017年开始担任Lexent Bio的独立董事，直到2020年该公司被Foundation Medicine收购。2011年至2015年，Klencke博士在Onyx制药公司担任全球开发高级副总裁，该公司于2013年被安进公司收购。2003年至2011年在基因泰克公司工作期间，她还领导了各种早期和晚期肿瘤学项目。她在加州大学旧金山分校完成了内科和血液学/肿瘤学培训，并在1995年至2002年期间继续担任肿瘤学助理教授，专注于临床研究。Klencke博士拥有印第安纳大学的学士学位和加州大学戴维斯分校的医学博士学位。
- Barbara Klencke has served as a member of TScan Therapeutics, Inc. board of directors since April 2023. She also currently serves as an independent board member of Xencor since September 2023 and Immune Onc Therapeutics, Inc. since 2022. She has previously served as an independent board member of ALX Oncology in 2025, eFFECTOR Therapeutics, Inc. from 2021 until 2024 and Lexent Bio from 2017 until that company's acquisition by Foundation Medicine in 2020. Dr. Klencke is currently serving as Chief Medical Officer of ALX Oncology, and previously served as the Chief Medical and Chief Development Officer of Sierra Oncology Inc. from 2015 until 2023 following its acquisition by GlaxoSmithKline plc in 2022. From 2011 to 2015, Dr. Klencke served as SVP, Global Development, at Onyx Pharmaceuticals, which was acquired by Amgen Inc., in 2013. She also led a variety of both early and late stage oncology programs while at Genentech, Inc. from 2003 to 2011. She completed Internal Medicine and Hematology/Oncology training at the University of California, San Francisco and remained there as an Assistant Professor of Medicine in Oncology focusing on clinical research from 1995 to 2002. Dr. Klencke holds a B.S. from Indiana University and an M.D. from the University of California, Davis.
- Gabriela Gruia
-
Gabriela Gruia自2021年5月起担任TScan Therapeutics董事会成员。Gruia博士于2021年1月创立了Gabriela Gruia咨询有限责任公司。在此之前，Gruia博士于2020年2月至2021年1月期间担任Ichnos Sciences Inc.的首席开发官，负责监管科学、临床运营、临床药理学、生物统计学和药物安全等多项关键职能。在加入Ichnos Sciences Inc.之前，Gruia博士曾于2008年2月至2020年2月担任诺华肿瘤学高级副总裁兼法规事务主管，负责领导肿瘤学法规事务组织。Gruia博士自2023年起担任Aprea Therapeutics，Inc.的董事会成员，自2023年起担任Netris Pharma，自2022年3月起担任Molecular Templates，Inc.的董事会成员，直至2024年12月解散。Gruia博士在罗马尼亚布加勒斯特医学院获得医学博士学位，并在法国巴黎的Rene Huguenin/Curie Institute癌症中心获得乳腺病理学和乳腺摄影硕士学位。她在法国巴黎勒内·笛卡尔大学接受了肿瘤学和血液学方面的培训。
Gabriela Gruia has served as a member of TScan Therapeutics, Inc. board of directors since May 2021. Dr. Gruia founded Gabriela Gruia Consulting, LLC in January 2021. Prior to that, Dr. Gruia served as the Chief Development Officer at Ichnos Sciences Inc. from February 2020 to January 2021, where she oversaw several key functions including Regulatory Sciences, Clinical Operations, Clinical Pharmacology, Biostatistics and Drug Safety. Prior to her time at Ichnos Sciences Inc., Dr. Gruia served as Senior Vice President and Head of Regulatory Affairs for Novartis Oncology from February 2008 through February 2020, where she was responsible for leading the oncology regulatory affairs organization. Dr. Gruia has served on the boards of directors for Aprea Therapeutics, Inc. since 2023, Netris Pharma since 2023, and Molecular Templates, Inc. from March 2022 until its dissolution in December 2024. Dr. Gruia received her doctorate in medicine from Bucharest Medical School in Romania and has a Masters in Breast Pathology and Mammography from Rene Huguenin/Curie Institute Cancer Center in Paris, France. She received her training in oncology and hematology from Rene Descartes University in Paris, France. - Gabriela Gruia自2021年5月起担任TScan Therapeutics董事会成员。Gruia博士于2021年1月创立了Gabriela Gruia咨询有限责任公司。在此之前，Gruia博士于2020年2月至2021年1月期间担任Ichnos Sciences Inc.的首席开发官，负责监管科学、临床运营、临床药理学、生物统计学和药物安全等多项关键职能。在加入Ichnos Sciences Inc.之前，Gruia博士曾于2008年2月至2020年2月担任诺华肿瘤学高级副总裁兼法规事务主管，负责领导肿瘤学法规事务组织。Gruia博士自2023年起担任Aprea Therapeutics，Inc.的董事会成员，自2023年起担任Netris Pharma，自2022年3月起担任Molecular Templates，Inc.的董事会成员，直至2024年12月解散。Gruia博士在罗马尼亚布加勒斯特医学院获得医学博士学位，并在法国巴黎的Rene Huguenin/Curie Institute癌症中心获得乳腺病理学和乳腺摄影硕士学位。她在法国巴黎勒内·笛卡尔大学接受了肿瘤学和血液学方面的培训。
- Gabriela Gruia has served as a member of TScan Therapeutics, Inc. board of directors since May 2021. Dr. Gruia founded Gabriela Gruia Consulting, LLC in January 2021. Prior to that, Dr. Gruia served as the Chief Development Officer at Ichnos Sciences Inc. from February 2020 to January 2021, where she oversaw several key functions including Regulatory Sciences, Clinical Operations, Clinical Pharmacology, Biostatistics and Drug Safety. Prior to her time at Ichnos Sciences Inc., Dr. Gruia served as Senior Vice President and Head of Regulatory Affairs for Novartis Oncology from February 2008 through February 2020, where she was responsible for leading the oncology regulatory affairs organization. Dr. Gruia has served on the boards of directors for Aprea Therapeutics, Inc. since 2023, Netris Pharma since 2023, and Molecular Templates, Inc. from March 2022 until its dissolution in December 2024. Dr. Gruia received her doctorate in medicine from Bucharest Medical School in Romania and has a Masters in Breast Pathology and Mammography from Rene Huguenin/Curie Institute Cancer Center in Paris, France. She received her training in oncology and hematology from Rene Descartes University in Paris, France.
- Garry Nicholson
-
Garry Nicholson，自2024年6月起担任董事会成员。Nicholson先生拥有超过35年的制药和生物技术肿瘤学经验。2015年8月至2016年11月，他担任XTuit Pharmaceuticals的总裁兼首席执行官，同时也是该公司的董事会成员。从2008年5月开始，他在辉瑞领导全球肿瘤专营权，直到2015年5月离职，担任辉瑞肿瘤学总裁。他的职责包括全球商业化和销售、临床开发和监管战略以及业务发展。在他的领导下，这家公司开发并推出了Ibrance（palbociclib），首个在美国和欧洲获批的细胞周期蛋白依赖性激酶（“CDK”）4/6抑制剂。在辉瑞任职期间，Nicholson先生曾担任辉瑞基金会的董事会成员，并且是公司投资组合、战略和投资委员会的成员，该委员会负责制定企业研发重点和投资战略。在其职业生涯的早期，尼科尔森先生曾在礼来公司的肿瘤部门担任过多个领导职务。此外，他还曾担任AMPATH的顾问，AMPATH是一个由北美大学和健康中心、莫伊大学、莫伊教学和转诊医院以及肯尼亚政府组成的联盟，后者帮助在发展中国家建立可持续的医疗保健系统。Nicholson先生的医疗保健职业生涯始于埃默里大学的药学实习生。他目前在私营生物制药公司Abdera Therapeutics Inc.担任董事会主席，并在上市的临床和商业阶段生物制药公司Day One Biopharmaceuticals, Inc.担任董事会主席。他目前还担任私营临床阶段公司Avenzo Therapeutics的董事会成员。Nicholson先生此前曾担任商业阶段公司G1治疗、上市临床阶段生物制药公司NextCure，上市公司临床阶段精准肿瘤学公司Turning Point Therapeutics, Inc.，上市临床阶段精准肿瘤学公司Five Prime Therapeutics, Inc.的董事会成员，上市临床阶段制药公司TERM3的董事会成员TESARO，Inc.，一家上市的专注于肿瘤学的生物制药公司，一家私营生物技术公司Tmunity Therapeutics Inc.，一家私营生物技术公司SQZ Biotechnologies，Inc.，一家私营生物技术公司，以及Personal Genome Diagnostics Inc.，一家私营癌症基因组学公司。尼科尔森先生拥有南卡罗来纳大学的工商管理硕士学位，并在北卡罗来纳大学教堂山分校获得药学学士学位。
Garry Nicholson has served as chair of Day One Biopharmaceuticals, Inc.'s board of directors since September 2022. From August 2015 to October 2016 he served as President and Chief Executive Officer of XTuit Pharmaceuticals, Inc., where he was also a member of the board of directors. Mr. Nicholson joined Pfizer, Inc. in May 2008 to lead the global oncology franchise, finishing his career there as President, Pfizer Oncology in April 2015. During his tenure at Pfizer, Mr. Nicholson served on the board of directors of the Pfizer Foundation and was a member of the company's Portfolio, Strategy and Investment Committee, which set corporate research and development priorities and investment strategy. Mr. Nicholson received a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina. - Garry Nicholson，自2024年6月起担任董事会成员。Nicholson先生拥有超过35年的制药和生物技术肿瘤学经验。2015年8月至2016年11月，他担任XTuit Pharmaceuticals的总裁兼首席执行官，同时也是该公司的董事会成员。从2008年5月开始，他在辉瑞领导全球肿瘤专营权，直到2015年5月离职，担任辉瑞肿瘤学总裁。他的职责包括全球商业化和销售、临床开发和监管战略以及业务发展。在他的领导下，这家公司开发并推出了Ibrance（palbociclib），首个在美国和欧洲获批的细胞周期蛋白依赖性激酶（“CDK”）4/6抑制剂。在辉瑞任职期间，Nicholson先生曾担任辉瑞基金会的董事会成员，并且是公司投资组合、战略和投资委员会的成员，该委员会负责制定企业研发重点和投资战略。在其职业生涯的早期，尼科尔森先生曾在礼来公司的肿瘤部门担任过多个领导职务。此外，他还曾担任AMPATH的顾问，AMPATH是一个由北美大学和健康中心、莫伊大学、莫伊教学和转诊医院以及肯尼亚政府组成的联盟，后者帮助在发展中国家建立可持续的医疗保健系统。Nicholson先生的医疗保健职业生涯始于埃默里大学的药学实习生。他目前在私营生物制药公司Abdera Therapeutics Inc.担任董事会主席，并在上市的临床和商业阶段生物制药公司Day One Biopharmaceuticals, Inc.担任董事会主席。他目前还担任私营临床阶段公司Avenzo Therapeutics的董事会成员。Nicholson先生此前曾担任商业阶段公司G1治疗、上市临床阶段生物制药公司NextCure，上市公司临床阶段精准肿瘤学公司Turning Point Therapeutics, Inc.，上市临床阶段精准肿瘤学公司Five Prime Therapeutics, Inc.的董事会成员，上市临床阶段制药公司TERM3的董事会成员TESARO，Inc.，一家上市的专注于肿瘤学的生物制药公司，一家私营生物技术公司Tmunity Therapeutics Inc.，一家私营生物技术公司SQZ Biotechnologies，Inc.，一家私营生物技术公司，以及Personal Genome Diagnostics Inc.，一家私营癌症基因组学公司。尼科尔森先生拥有南卡罗来纳大学的工商管理硕士学位，并在北卡罗来纳大学教堂山分校获得药学学士学位。
- Garry Nicholson has served as chair of Day One Biopharmaceuticals, Inc.'s board of directors since September 2022. From August 2015 to October 2016 he served as President and Chief Executive Officer of XTuit Pharmaceuticals, Inc., where he was also a member of the board of directors. Mr. Nicholson joined Pfizer, Inc. in May 2008 to lead the global oncology franchise, finishing his career there as President, Pfizer Oncology in April 2015. During his tenure at Pfizer, Mr. Nicholson served on the board of directors of the Pfizer Foundation and was a member of the company's Portfolio, Strategy and Investment Committee, which set corporate research and development priorities and investment strategy. Mr. Nicholson received a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina.
- R. Keith Woods
-
R. Keith Woods自2023年12月起担任TScan Therapeutics董事会成员。伍兹先生在生物制药领域拥有超过三十年的经验。自2025年4月起，担任Scholar Rock首席运营官。Woods先生此前曾于2018年4月至2023年6月担任argenx美国公司的首席运营官，在那里他领导公司完成了从研发机构到全球商业机构的转变。在此期间，他监督了为argenx首次产品发布做准备的关键团队，包括销售、市场营销、市场准入和报销、业务运营、患者服务和医疗事务。2023年，Woods先生从这一职位过渡到担任argenx董事会的战略商业顾问。在加入argenx之前，Woods先生曾在亚力兄制药公司担任北美业务高级副总裁，在美国和加拿大他管理着一个数百人的团队，负责超过10亿美元的年销售额。在加入Alexion之前，Woods先生曾在罗氏、安进和卫材株式会社担任过多个职位，责任越来越大，任职时间跨度为20年。Woods先生目前在Neurogene Inc.的董事会任职，此前曾在X4制药，Inc.和Rocket制药公司的董事会任职。他拥有佛罗里达州立大学市场营销理学学士学位。
R. Keith Woods has served as a member of TScan Therapeutics, Inc. board of directors since December 2023. Mr. Woods has over three decades of experience in the biopharmaceutical sector. Since April 2025, he has served as Chief Operating Officer of Scholar Rock. Mr. Woods previously served as Chief Operating Officer of argenx U.S. Inc., from April 2018 to June 2023, where he led the company through its transition from an R&D organization to a global commercial organization. During this time, he oversaw key teams in preparation for argenx's first product launch, including sales, marketing, market access and reimbursement, business operations, patient services and medical affairs. In 2023, Mr. Woods transitioned from this role to serve as a strategic commercial advisor to the board of directors of argenx. Prior to argenx, Mr. Woods served as senior vice president of North American operations for Alexion Pharmaceuticals, Inc., where he managed a team of several hundred people in the U.S. and Canada and was responsible for more than $1 billion in annual sales. Prior to joining Alexion, Mr. Woods held various positions of increasing responsibility within Roche, Amgen, and Eisai Co., Ltd., over a span of 20 years. Mr. Woods currently serves on the board of directors of Neurogene Inc., and he previously served on the board of directors of X4 Pharmaceuticals, Inc. and Rocket Pharmaceuticals, Inc. He holds a Bachelor of Science in marketing from Florida State University. - R. Keith Woods自2023年12月起担任TScan Therapeutics董事会成员。伍兹先生在生物制药领域拥有超过三十年的经验。自2025年4月起，担任Scholar Rock首席运营官。Woods先生此前曾于2018年4月至2023年6月担任argenx美国公司的首席运营官，在那里他领导公司完成了从研发机构到全球商业机构的转变。在此期间，他监督了为argenx首次产品发布做准备的关键团队，包括销售、市场营销、市场准入和报销、业务运营、患者服务和医疗事务。2023年，Woods先生从这一职位过渡到担任argenx董事会的战略商业顾问。在加入argenx之前，Woods先生曾在亚力兄制药公司担任北美业务高级副总裁，在美国和加拿大他管理着一个数百人的团队，负责超过10亿美元的年销售额。在加入Alexion之前，Woods先生曾在罗氏、安进和卫材株式会社担任过多个职位，责任越来越大，任职时间跨度为20年。Woods先生目前在Neurogene Inc.的董事会任职，此前曾在X4制药，Inc.和Rocket制药公司的董事会任职。他拥有佛罗里达州立大学市场营销理学学士学位。
- R. Keith Woods has served as a member of TScan Therapeutics, Inc. board of directors since December 2023. Mr. Woods has over three decades of experience in the biopharmaceutical sector. Since April 2025, he has served as Chief Operating Officer of Scholar Rock. Mr. Woods previously served as Chief Operating Officer of argenx U.S. Inc., from April 2018 to June 2023, where he led the company through its transition from an R&D organization to a global commercial organization. During this time, he oversaw key teams in preparation for argenx's first product launch, including sales, marketing, market access and reimbursement, business operations, patient services and medical affairs. In 2023, Mr. Woods transitioned from this role to serve as a strategic commercial advisor to the board of directors of argenx. Prior to argenx, Mr. Woods served as senior vice president of North American operations for Alexion Pharmaceuticals, Inc., where he managed a team of several hundred people in the U.S. and Canada and was responsible for more than $1 billion in annual sales. Prior to joining Alexion, Mr. Woods held various positions of increasing responsibility within Roche, Amgen, and Eisai Co., Ltd., over a span of 20 years. Mr. Woods currently serves on the board of directors of Neurogene Inc., and he previously served on the board of directors of X4 Pharmaceuticals, Inc. and Rocket Pharmaceuticals, Inc. He holds a Bachelor of Science in marketing from Florida State University.
高管简历
中英对照 | 中文 | 英文- Zoran Zdraveski
Zoran Zdraveski自2017年4月起担任我们的首席法务官。Zdraveski博士负责Magenta’；的法律、知识产权和合规职能的所有方面。Zdraveski博士在生物制药行业的法律领域拥有超过16年的经验。最近，他于2012年7月至2017年4月担任Epizyme Inc.（Epizyme）的Vice President兼副总法律顾问，在该公司2013年首次公开募股前后，他建立了法律团队，并管理法律，知识产权和合规性的所有方面。加入Epizyme公司之前，他曾担任Ironwood公司（从2011年4月到2012年7月）、Genzyme Therapeutics公司（从2009年9月到2011年4月）的专利顾问职务。Zdraveski博士在麻省理工学院（Massachusetts Institute of Technology）获得生物化学博士学位，在萨福克大学法学院（Suffolk University Law School）获得法学博士学位，在南卫理公会大学（Southern Methodist University）获得化学研究生学位和化学与工作室艺术本科生学位。
Zoran Zdraveski has served as TScan Therapeutics, Inc. Chief Legal and Strategy Officer and Secretary since September 2021. He has more than 20 years of legal, intellectual property and business operations experience in the biopharmaceutical industry. Prior to joining TScan, from April 2017 to April 2021, Dr. Zdraveski served as the Chief Legal and Technology Operations Officer at Magenta Therapeutics Inc., where he established the legal team and managed all aspects of legal, intellectual property and compliance both before and after Magenta's 2018 initial public offering. Prior to Magenta, he was the Vice President and Associate General Counsel at Epizyme Inc. from July 2012 to April 2017. Prior to joining Epizyme, he held patent counsel positions at Ironwood and Genzyme Therapeutics. Dr. Zdraveski currently serves as chair of the board of gMendel Aps and has been a director of the board of gMendel Aps since 2023. Dr. Zdraveski holds an M.S. in Chemistry and a B.F.A. and B.A. in Art and Chemistry from Southern Methodist University, a J.D. from Suffolk University Law School, and a Ph.D. in Biochemistry from the Massachusetts Institute of Technology.- Zoran Zdraveski自2017年4月起担任我们的首席法务官。Zdraveski博士负责Magenta’；的法律、知识产权和合规职能的所有方面。Zdraveski博士在生物制药行业的法律领域拥有超过16年的经验。最近，他于2012年7月至2017年4月担任Epizyme Inc.（Epizyme）的Vice President兼副总法律顾问，在该公司2013年首次公开募股前后，他建立了法律团队，并管理法律，知识产权和合规性的所有方面。加入Epizyme公司之前，他曾担任Ironwood公司（从2011年4月到2012年7月）、Genzyme Therapeutics公司（从2009年9月到2011年4月）的专利顾问职务。Zdraveski博士在麻省理工学院（Massachusetts Institute of Technology）获得生物化学博士学位，在萨福克大学法学院（Suffolk University Law School）获得法学博士学位，在南卫理公会大学（Southern Methodist University）获得化学研究生学位和化学与工作室艺术本科生学位。
- Zoran Zdraveski has served as TScan Therapeutics, Inc. Chief Legal and Strategy Officer and Secretary since September 2021. He has more than 20 years of legal, intellectual property and business operations experience in the biopharmaceutical industry. Prior to joining TScan, from April 2017 to April 2021, Dr. Zdraveski served as the Chief Legal and Technology Operations Officer at Magenta Therapeutics Inc., where he established the legal team and managed all aspects of legal, intellectual property and compliance both before and after Magenta's 2018 initial public offering. Prior to Magenta, he was the Vice President and Associate General Counsel at Epizyme Inc. from July 2012 to April 2017. Prior to joining Epizyme, he held patent counsel positions at Ironwood and Genzyme Therapeutics. Dr. Zdraveski currently serves as chair of the board of gMendel Aps and has been a director of the board of gMendel Aps since 2023. Dr. Zdraveski holds an M.S. in Chemistry and a B.F.A. and B.A. in Art and Chemistry from Southern Methodist University, a J.D. from Suffolk University Law School, and a Ph.D. in Biochemistry from the Massachusetts Institute of Technology.
- Gavin MacBeath
Gavin MacBeath自2023年5月起担任TScan Therapeutics，Inc.首席执行官和TScan Therapeutics，Inc.董事会成员。他此前于2023年3月至2023年5月担任TScan Therapeutics，Inc.代理首席执行官，于2018年12月至2023年5月担任TScan Therapeutics，Inc.首席科学和运营官。他在学术界和工业界拥有超过二十年的经验，创立公司并推动研究从早期发现到药物批准。在加入TScan之前，MacBeath博士于2017年3月至2018年7月在Abpro Corporation担任首席科学官，通过临床前开发推进T细胞接合双特异性抗体。此前，MacBeath博士是Merrimack制药的联合创始人，曾于2010年2月至2014年2月担任转化研究主管，并于2014年2月至2016年10月担任Discovery高级副总裁。麦克比思博士的学术生涯始于此，他曾担任哈佛大学鲍尔基因组学研究中心的首位研究员，担任哈佛大学化学与化学生物学系的助理教授和后来的副教授，并担任哈佛医学院的讲师和首席研究员。MacBeath博士在马尼托巴大学获得本科学位，在斯克里普斯研究所获得博士学位，并在哈佛大学与Stuart Schreiber博士一起接受博士后培训。
Gavin MacBeath has served as TScan Therapeutics, Inc. Chief Executive Officer and as a member of TScan Therapeutics, Inc. board of directors since May 2023. He was previously TScan Therapeutics, Inc. acting Chief Executive Officer from March 2023 to May 2023, and TScan Therapeutics, Inc. Chief Scientific and Operating Officer from December 2018 to May 2023. He has over two decades of experience in academia and industry, founding companies and driving research from early stage discovery through drug approval. Prior to joining TScan, Dr. MacBeath served as the Chief Scientific Officer at Abpro Corporation from March 2017 to July 2018, where he advanced T cell engaging bispecific antibodies through pre clinical development. Previously, Dr. MacBeath was a co founder of Merrimack Pharmaceuticals, where he served as Head of Translational Research from February 2010 to February 2014 and as Senior Vice President of Discovery from February 2014 to October 2016. Dr. MacBeath began his career in academia, where he served as the first fellow at Harvard's Bauer Center for Genomics Research, as an Assistant Professor and later Associate Professor in the Department of Chemistry & Chemical Biology at Harvard University, and as Lecturer and Principal Investigator at Harvard Medical School. Dr. MacBeath received his undergraduate degree from the University of Manitoba, his Ph.D. from The Scripps Research Institute, and postdoctoral training with Dr. Stuart Schreiber at Harvard University.- Gavin MacBeath自2023年5月起担任TScan Therapeutics，Inc.首席执行官和TScan Therapeutics，Inc.董事会成员。他此前于2023年3月至2023年5月担任TScan Therapeutics，Inc.代理首席执行官，于2018年12月至2023年5月担任TScan Therapeutics，Inc.首席科学和运营官。他在学术界和工业界拥有超过二十年的经验，创立公司并推动研究从早期发现到药物批准。在加入TScan之前，MacBeath博士于2017年3月至2018年7月在Abpro Corporation担任首席科学官，通过临床前开发推进T细胞接合双特异性抗体。此前，MacBeath博士是Merrimack制药的联合创始人，曾于2010年2月至2014年2月担任转化研究主管，并于2014年2月至2016年10月担任Discovery高级副总裁。麦克比思博士的学术生涯始于此，他曾担任哈佛大学鲍尔基因组学研究中心的首位研究员，担任哈佛大学化学与化学生物学系的助理教授和后来的副教授，并担任哈佛医学院的讲师和首席研究员。MacBeath博士在马尼托巴大学获得本科学位，在斯克里普斯研究所获得博士学位，并在哈佛大学与Stuart Schreiber博士一起接受博士后培训。
- Gavin MacBeath has served as TScan Therapeutics, Inc. Chief Executive Officer and as a member of TScan Therapeutics, Inc. board of directors since May 2023. He was previously TScan Therapeutics, Inc. acting Chief Executive Officer from March 2023 to May 2023, and TScan Therapeutics, Inc. Chief Scientific and Operating Officer from December 2018 to May 2023. He has over two decades of experience in academia and industry, founding companies and driving research from early stage discovery through drug approval. Prior to joining TScan, Dr. MacBeath served as the Chief Scientific Officer at Abpro Corporation from March 2017 to July 2018, where he advanced T cell engaging bispecific antibodies through pre clinical development. Previously, Dr. MacBeath was a co founder of Merrimack Pharmaceuticals, where he served as Head of Translational Research from February 2010 to February 2014 and as Senior Vice President of Discovery from February 2014 to October 2016. Dr. MacBeath began his career in academia, where he served as the first fellow at Harvard's Bauer Center for Genomics Research, as an Assistant Professor and later Associate Professor in the Department of Chemistry & Chemical Biology at Harvard University, and as Lecturer and Principal Investigator at Harvard Medical School. Dr. MacBeath received his undergraduate degree from the University of Manitoba, his Ph.D. from The Scripps Research Institute, and postdoctoral training with Dr. Stuart Schreiber at Harvard University.
- Jason A. Amello
Jason A. Amello自2024年1月起担任TScan Therapeutics，Inc. 首席财务官并担任财务主管。在加入TScan之前，2022年9月至2024年1月，Amello先生在Candel Therapeutics, Inc.担任首席财务官、财务主管和秘书。在加入Candel之前，Amello先生于2020年9月至2022年4月担任Saniona AB的首席财务官和财务主管，并于2013年9月至2020年8月担任高级副总裁、首席财务官和Akebia Therapeutics，Inc.的财务主管。Amello先生还曾于2012年5月至2013年5月担任Alaunos Therapeutics, Inc.（原名ZIOPHARM Oncology，Inc.）的执行副总裁、首席财务官和财务主管。从2000年4月到2011年6月，Amello先生在健赞（已被赛诺菲收购）担任过各种职责日益增加的职位，包括高级副总裁、首席会计官和公司财务总监，还领导战略金融服务集团，通过该集团，他在Genzyme的所有并购和其他战略交易中担任关键顾问，包括将公司出售给赛诺菲。在其职业生涯的早期，Amello先生曾在德勤的商业咨询和保证实践中工作了十年，通过高级经理担任各种职责不断增加的角色。自2017年10月起，Amello先生担任Acer医疗，Inc.的董事会成员，直至2023年11月该公司被Zevra Therapeutics收购并担任其审计委员会主席。Amello先生还在2015年至2023年期间担任新英格兰浸会医院的董事会成员，并担任护理质量委员会主席和财务和投资委员会成员。Amello先生在波士顿学院获得会计学学士学位，是马萨诸塞州联邦的注册会计师。
Jason A. Amello has served as TScan Therapeutics, Inc. Chief Financial Officer and Treasurer since January 2024. Prior to joining TScan, from September 2022 to January 2024, Mr. Amello was the Chief Financial Officer, Treasurer and Secretary at Candel Therapeutics, Inc. Prior to Candel, Mr. Amello served as Chief Financial Officer and Treasurer of Saniona AB from September 2020 to April 2022, and Senior Vice President, Chief Financial Officer and Treasurer of Akebia Therapeutics, Inc. from September 2013 to August 2020. Mr. Amello was also Executive Vice President, Chief Financial Officer and Treasurer of Alaunos Therapeutics, Inc. (formerly known as ZIOPHARM Oncology, Inc.) from May 2012 to May 2013. From April 2000 until June 2011, Mr. Amello served in various positions of increasing responsibility at Genzyme Corporation (acquired by Sanofi), including Senior Vice President, Chief Accounting Officer and Corporate Controller, and also led the Strategic Financial Services group through which he served as a key advisor on all of Genzyme's mergers and acquisitions and other strategic transactions, including the sale of the company to Sanofi. Earlier in his career, Mr. Amello spent ten years in the business advisory and assurance practice of Deloitte, serving in various roles of increasing responsibility through Senior Manager. Since October 2017, Mr. Amello served as a member of the Board of Directors of Acer Therapeutics, Inc. until its acquisition by Zevra Therapeutics in November 2023 and was chairman of its audit committee. Mr. Amello also served on the Board of Directors of New England Baptist Hospital from 2015 to 2023 and was chairman of the Quality of Care Committee and a member of the Finance and Investment Committee. Mr. Amello received his B.S. in accounting from Boston College and is a Certified Public Accountant in the Commonwealth of Massachusetts.- Jason A. Amello自2024年1月起担任TScan Therapeutics，Inc. 首席财务官并担任财务主管。在加入TScan之前，2022年9月至2024年1月，Amello先生在Candel Therapeutics, Inc.担任首席财务官、财务主管和秘书。在加入Candel之前，Amello先生于2020年9月至2022年4月担任Saniona AB的首席财务官和财务主管，并于2013年9月至2020年8月担任高级副总裁、首席财务官和Akebia Therapeutics，Inc.的财务主管。Amello先生还曾于2012年5月至2013年5月担任Alaunos Therapeutics, Inc.（原名ZIOPHARM Oncology，Inc.）的执行副总裁、首席财务官和财务主管。从2000年4月到2011年6月，Amello先生在健赞（已被赛诺菲收购）担任过各种职责日益增加的职位，包括高级副总裁、首席会计官和公司财务总监，还领导战略金融服务集团，通过该集团，他在Genzyme的所有并购和其他战略交易中担任关键顾问，包括将公司出售给赛诺菲。在其职业生涯的早期，Amello先生曾在德勤的商业咨询和保证实践中工作了十年，通过高级经理担任各种职责不断增加的角色。自2017年10月起，Amello先生担任Acer医疗，Inc.的董事会成员，直至2023年11月该公司被Zevra Therapeutics收购并担任其审计委员会主席。Amello先生还在2015年至2023年期间担任新英格兰浸会医院的董事会成员，并担任护理质量委员会主席和财务和投资委员会成员。Amello先生在波士顿学院获得会计学学士学位，是马萨诸塞州联邦的注册会计师。
- Jason A. Amello has served as TScan Therapeutics, Inc. Chief Financial Officer and Treasurer since January 2024. Prior to joining TScan, from September 2022 to January 2024, Mr. Amello was the Chief Financial Officer, Treasurer and Secretary at Candel Therapeutics, Inc. Prior to Candel, Mr. Amello served as Chief Financial Officer and Treasurer of Saniona AB from September 2020 to April 2022, and Senior Vice President, Chief Financial Officer and Treasurer of Akebia Therapeutics, Inc. from September 2013 to August 2020. Mr. Amello was also Executive Vice President, Chief Financial Officer and Treasurer of Alaunos Therapeutics, Inc. (formerly known as ZIOPHARM Oncology, Inc.) from May 2012 to May 2013. From April 2000 until June 2011, Mr. Amello served in various positions of increasing responsibility at Genzyme Corporation (acquired by Sanofi), including Senior Vice President, Chief Accounting Officer and Corporate Controller, and also led the Strategic Financial Services group through which he served as a key advisor on all of Genzyme's mergers and acquisitions and other strategic transactions, including the sale of the company to Sanofi. Earlier in his career, Mr. Amello spent ten years in the business advisory and assurance practice of Deloitte, serving in various roles of increasing responsibility through Senior Manager. Since October 2017, Mr. Amello served as a member of the Board of Directors of Acer Therapeutics, Inc. until its acquisition by Zevra Therapeutics in November 2023 and was chairman of its audit committee. Mr. Amello also served on the Board of Directors of New England Baptist Hospital from 2015 to 2023 and was chairman of the Quality of Care Committee and a member of the Finance and Investment Committee. Mr. Amello received his B.S. in accounting from Boston College and is a Certified Public Accountant in the Commonwealth of Massachusetts.
- Chrystal Louis
Chrystal Louis自2024年4月起担任TScan Therapeutics，公司首席医疗官。在加入TScan之前，从2022年11月到2024年3月，Louis博士在Zentalis Pharmaceuticals, Inc.担任血液学临床开发高级副总裁。在加入Zentalis之前，Louis博士从2020年7月到2022年11月在CRISPR Therapeutics，Inc.担任副总裁兼医疗事务主管。从2016年10月到2020年7月，Louis博士曾在新基医药公司（被百时美施贵宝公司收购）担任多个职责日益增加的职位，包括美国医疗事务骨髓病执行董事、美国医疗事务肿瘤学执行董事以及美国医疗事务胰腺/胃肠道疾病主管执行董事。从2014年9月到2016年10月，Louis博士还在Merrimack Pharmaceuticals, Inc.担任临床开发和项目领导战略职务。在加入行业之前，Louis博士是贝勒医学院德克萨斯儿童癌症中心和血液学服务中心的助理教授，在那里她致力于实体瘤恶性肿瘤CAR T细胞治疗产品的早期开发。路易斯在杜兰大学医学院获得医学博士学位，在杜兰大学公共卫生和热带医学学院获得公共卫生硕士学位，在德克萨斯州乔治敦西南大学获得政治学学士学位和化学学士学位。
Chrystal Louis has served as TScan Therapeutics, Inc. Chief Medical Officer since April 2024. Prior to joining TScan, from November 2022 to March 2024, Dr. Louis was the Senior Vice President of hematology clinical development at Zentalis Pharmaceuticals, Inc. Prior to Zentalis, Dr. Louis served as Vice President, Head of Medical Affairs at CRISPR Therapeutics, Inc. from July 2020 to November 2022. From October 2016 to July 2020, Dr. Louis served in various positions of increasing responsibility at Celgene Corporation (acquired by Bristol Myers Squibb Company), including Executive Director, Myeloid Diseases, U.S. Medical Affairs, Executive Director, Oncology, U.S. Medical Affairs and Executive Director, Pancreatic/GI Disease Lead, U.S. Medical Affairs. From September 2014 to October 2016, Dr Louis also served in the role of clinical development and project leadership strategy at Merrimack Pharmaceuticals, Inc. Prior to joining industry, Dr. Louis was an Assistant Professor at Texas Children's Cancer Center and Hematology Service, Baylor College of Medicine, where she worked on the early development of CAR T cell therapy products for solid tumor malignancies.Dr. Louis received her M.D. from Tulane University School of Medicine, her Masters Degree in Public Health from Tulane University School of Public Health and Tropical Medicine, and her B.A. in Political Science and B.S. in Chemistry from Southwestern University at Georgetown, TX.- Chrystal Louis自2024年4月起担任TScan Therapeutics，公司首席医疗官。在加入TScan之前，从2022年11月到2024年3月，Louis博士在Zentalis Pharmaceuticals, Inc.担任血液学临床开发高级副总裁。在加入Zentalis之前，Louis博士从2020年7月到2022年11月在CRISPR Therapeutics，Inc.担任副总裁兼医疗事务主管。从2016年10月到2020年7月，Louis博士曾在新基医药公司（被百时美施贵宝公司收购）担任多个职责日益增加的职位，包括美国医疗事务骨髓病执行董事、美国医疗事务肿瘤学执行董事以及美国医疗事务胰腺/胃肠道疾病主管执行董事。从2014年9月到2016年10月，Louis博士还在Merrimack Pharmaceuticals, Inc.担任临床开发和项目领导战略职务。在加入行业之前，Louis博士是贝勒医学院德克萨斯儿童癌症中心和血液学服务中心的助理教授，在那里她致力于实体瘤恶性肿瘤CAR T细胞治疗产品的早期开发。路易斯在杜兰大学医学院获得医学博士学位，在杜兰大学公共卫生和热带医学学院获得公共卫生硕士学位，在德克萨斯州乔治敦西南大学获得政治学学士学位和化学学士学位。
- Chrystal Louis has served as TScan Therapeutics, Inc. Chief Medical Officer since April 2024. Prior to joining TScan, from November 2022 to March 2024, Dr. Louis was the Senior Vice President of hematology clinical development at Zentalis Pharmaceuticals, Inc. Prior to Zentalis, Dr. Louis served as Vice President, Head of Medical Affairs at CRISPR Therapeutics, Inc. from July 2020 to November 2022. From October 2016 to July 2020, Dr. Louis served in various positions of increasing responsibility at Celgene Corporation (acquired by Bristol Myers Squibb Company), including Executive Director, Myeloid Diseases, U.S. Medical Affairs, Executive Director, Oncology, U.S. Medical Affairs and Executive Director, Pancreatic/GI Disease Lead, U.S. Medical Affairs. From September 2014 to October 2016, Dr Louis also served in the role of clinical development and project leadership strategy at Merrimack Pharmaceuticals, Inc. Prior to joining industry, Dr. Louis was an Assistant Professor at Texas Children's Cancer Center and Hematology Service, Baylor College of Medicine, where she worked on the early development of CAR T cell therapy products for solid tumor malignancies.Dr. Louis received her M.D. from Tulane University School of Medicine, her Masters Degree in Public Health from Tulane University School of Public Health and Tropical Medicine, and her B.A. in Political Science and B.S. in Chemistry from Southwestern University at Georgetown, TX.